Kylie McLaughlin
Associate Principal Scientist at CV6 Therapeutics, (NI) Ltd.- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
Topline Score
Bio
Credentials
-
Fellow of Institute of Biomedical Science
Institute of Biomedical ScienceFeb, 2017- Nov, 2024
Experience
-
CV6 Therapeutics, (NI) Ltd.
-
United Kingdom
-
Pharmaceutical Manufacturing
-
1 - 100 Employee
-
Associate Principal Scientist
-
Nov 2022 - Present
-
-
Drug Development Senior Scientist
-
Jul 2015 - Nov 2022
-
-
-
Queen's University Belfast
-
United Kingdom
-
Higher Education
-
700 & Above Employee
-
Visiting Scholar
-
Jul 2015 - Present
-
-
Research Assistant
-
May 2015 - Jul 2015
-
-
Research PhD Student
-
Sep 2011 - Jul 2015
As a member of Patrick Johnston’s drug resistance group and Kevin Prise’s radiation biology group at the Patrick Johnston Centre for Cancer Research I completed my doctoral research on the role of FLIP as a novel regulator of resistance to ionising radiation.
-
-
Laboratory Demonstrator
-
Sep 2012 - Jan 2013
Demonstration and teaching of laboratory molecular biology techniques for School of Biological Sciences undergraduate year 2 module - Molecular Genetics.
-
-
Teaching Assistant
-
Sep 2011 - Jun 2012
Teaching assistance for 2 modules as part of undergraduate medical program. "Cell, Tissues & Organs: Foundations of Clinical Practice I and II"
-
-
-
Karolinska Institutet
-
Sweden
-
Higher Education
-
700 & Above Employee
-
Visiting Researcher
-
Jul 2011 - Sep 2011
Bertrand Joseph lab @ Cancer centrum Bertrand Joseph lab @ Cancer centrum
-
-
-
Queen's University Belfast
-
United Kingdom
-
Higher Education
-
700 & Above Employee
-
Summer Research Student
-
Jul 2010 - Aug 2010
Within the drug resistance group I worked with HDAC inhibitors and chemotherapy in colorectal cancer models. Contributed to publication: Kerr, E. et al. Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death and Differentiation 1–11 (2012). doi:10.1038/cdd.2012.8 Within the drug resistance group I worked with HDAC inhibitors and chemotherapy in colorectal cancer models. Contributed to publication: Kerr, E. et al. Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death and Differentiation 1–11 (2012). doi:10.1038/cdd.2012.8
-
-
Education
-
Queen's University Belfast
Doctor of Philosophy (PhD), Medicine (Oncology) -
Queen's University Belfast
Biomedical Science, Biomedical Sciences, General -
University of South Wales
Foundation Degree in Applied Sciences, Pre-Chiropractic Studies